hereby certify that this paper (along with any paper referred to as being attached thinclosed) is being deposited with the U.S. Postal Service on the date shown with sufficient postage as First Class Mail, in an envelope addressed to: strention: Certificate of Correction Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: January 17, 2008

Signature: (I vnn I Janvijs)

Docket No.: 01017/35966C (PATENT)

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Letters Patent of: Hui-Quan Han et al.

Patent No.: 7,220,547

Issued: May 22, 2007

For: HUMAN E3 ALPHA UBIQUITIN LIGASE

**FAMILY** 

# REQUEST FOR CERTIFICATE OF CORRECTION PURSUANT TO 37 C.F.R. § 1.323

Attention: Certificate of Correction Branch Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 JAN 2 5 2008

Dear Sir:

Upon reviewing the above-identified patent, Patentee noted typographical errors which should be corrected.

On the First Page:

At field (73), PTO error, "Amgen, Inc." should be -- Amgen Inc. --.

In the Drawings:

At Sheet 20, Fig. 9, row label, Applicant error, "Gastroenmius" should be -- Gastroenmius --.

At Sheet 21, Fig. 10, header, line 2, Applicant error, "myostube" should be --

01/23/2008 SDIRETA1 00000002 7220547

myotube --.

01 FC:1811

100.00 OP

RECEIVED-USPTO

JAN 2 5 2008

## In the Specification:

At page 5, line 12, PTO error, "0.16" should be -- 16 --.

At page 6, line 4, PTO error, "f)," should be -- f) --.

At page 8, line 24, Applicant error, "polypeptide comprising." should be -- polypeptide --.

At page 12, line 19, Applicant error, "encompasses" should be -- encompass --

At page 12, line 21, PTO error, "-N-6-" should be -- -N6- --.

At page 12, line 29, PTO error, "-N-6-" should be -- -N6- --.

At page 16, line 10, PTO error, "alt" should be -- art --.

At page 17, line 22, PTO error, "25from" should be-- 25, or from --.

At page 19, line 11, Applicant error, "a its hydropathic" should be -- a hydropathic --.

At page 19, line 13, PTO error, "phenylalamine" should be -- phenylalanine --.

At page 21, line 21, Applicant error, "IN" should be -- In --.

At page 22, line 4, Applicant error, "using through" should be -- using --.

At page 22, line 9, PTO error, "constructed" should be -- constructed, --.

At page 24, line 13, PTO error, "Included %" should be -- Included --.

At page 26, line 13, Applicant error, "huE3αpolypeptide" should be -- huE3α polypeptide --.

At page 29, line 8, PTO error, "normative" should be -- nonnative --.

At page 32, line 24, PTO error, "diagonal" should be -- diagonal" --.

At page 32, line 27, PTO error, "penalty." should be -- penalty --.

At page 46, lines 12-13, Applicant error, "refers a" should be -- refers to a --.

At page 49, line 20, Applicant error, "example, using an" should be -- example, an --.

In the Preliminary Amendment dated January 15, 2004, page 3, line 24, Applicant error, "6 kD" should be -- 6 kDa --.

In the Preliminary Amendment dated January 15, 2004, page 3, line 24, PTO error, "carbohydrat-based" should be -- carbohydrate-based --.

In the Preliminary Amendment dated January 15, 2004, page 6, line 2, PTO error, "about." should be -- about --.

At page 59, line 2, Applicant error, "set of has" should be -- set of test molecules has --

In the Preliminary Amendment dated January 15, 2004, page 7, line 21, Applicant error, "to polypeptide" should be -- to the polypeptide --.

At page 67, line 30, PTO error, "isonixim" should be -- isonixirn --.

At page 68, line 3, PTO error, "KCNTE16090" should be -- KCNTEI6090 ---

At page 68, line 33, PTO error, "triaamcinolone acetonide" should be -- triamcinolone acetonide --.

At page 69, line 12, PTO error, "aurothioglycamide" should be -- aurothioglycanide --.

At page 70, line 3, PTO error, "cephalosporinns" should be -- cephalosporins -

At page 80, line 16, PTO error, "527.1994" should be -- 527, 1994 --.

At page 81, line 1, PTO error, "sequence. (c)" should be -- sequence, (c) --.

At page 82, line 18, PTO error, "5,106.627" should be -- 5,106,627 ---

At page 86, line 13, PTO error, "constrict" should be -- construct --.

At page 89, line 14, Applicant error, "85oC" should be -- 85°C --.

4

At page 91, line 20, Applicant error, "clone of was" should be -- clone was --.

At page 92, line 5, Applicant error, "hour" should be -- hours --.

At page 92, line 14, Applicant error, "including" should be -- including --.

At page 94, line 12, Applicant error, "Edition", Edition," should be -- Edition,

At page 95, line 11, PTO error, "oil" should be -- on --.

At page 95, line 22, PTO error, "0.20%" should be -- 20% --.

At page 97, line 2, PTO error, "follows: 5" should be -- follows: --.

At page 98, line 9, Applicant error, "50 ug/ml" should be -- 50 μg/ml --.

At page 98, line 31, Applicant error, "MgCl2" should be -- MgCl2 --.

At page 99, line 31, PTO error, "epitroclielaris" should be -- epitrochelaris --.

At page 100, line 28, Applicant error, "MgCl2" should be -- MgCl2 --.

At page 100, line 29, Applicant error, "125I" should be -- 125I -- RECEIVED-USETO

At page 101, line 32, Applicant error, "avaiblae" should be -- available --.

At page 103, line 30, Applicant error, "tehrere" should be -- there --.

At page 104, line 1, Applicant error, "decease" should be -- decrease --.

### In the Claims:


In the Examiner's Amendment, page 4, line 9, PTO error, "(a); or (b)" should be -- (a) --.

In the Examiner's Amendment, page 4, line 14, PTO error, "to any" should be -- to the full length of any --.

The errors were found in the application as filed by Applicant and also by the Patent Office. Our check in the amount of \$100.00 covering the fee set forth in 37 C.F.R. § 1.20(a) is enclosed.

The errors now sought to be corrected are inadvertent typographical errors the correction of which does not involve new matter or require reexamination.

Transmitted herewith is a proposed Certificate of Correction effecting such amendment. Patentee respectfully solicits the granting of the requested Certificate of Correction.



The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 13-2855, under Order No. 01017/35966C.

Dated: January 17, 2008

Respectfully submitted,

Lynn L. Janulis

Registration No.: 53,066
Agent for Applicant/Patentee

MARSHALL, GERSTEIN & BORUN LLP

233 S. Wacker Drive, Suite 6300

Sears Tower

Chicago, Illinois 60606-6357

(312) 474-6300

## UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

Page 1 of 4

PATENT NO.

7,220,547

APPLICATION NO. :

10/758.636

ISSUE DATE

May 22, 2007

INVENTOR(S)

Hui-Quan Han et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

#### On the First Page:

At field (73), "Amgen, Inc." should be -- Amgen Inc. --.

#### In the Drawings:

At Sheet 20, Fig. 9, row label, "Gastroenmius" should be -- Gastrocnemius --.

At Sheet 21, Fig. 10, header, line 2, "myostube" should be -- myotube --.

#### In the Specification:

At Column 4, line 2, "0.16" should be -- 16 --.

At Column 4, line 33, "f)," should be -- f) --.

At Column 6, line 8, "polypeptide comprising." should be -- polypeptide --.

At Column 8, line 39, "encompasses" should be -- encompass --.

At Column 8, line 41, "-N-6-" should be -- -N6- --.

At Column 8, line 52, "-N-6-" should be -- -N6- --.

At Column 10, line 66, "alt" should be -- art --.


At Column 11, line 61, "25from" should be-- 25, or from --.

MAILING ADDRESS OF SENDER (Please do not use customer number below): Lynn L. Janulis

MARSHALL, GERSTEIN & BORUN LLP 233 S. Wacker Drive, Suite 6300

Sears Tower

Chicago, Illinois 60606-6357



### (Also Form PTO-1050)

# UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

Page \_2\_ of \_4\_

At Column 13, line 3, "a its hydropathic" should be -- a hydropathic --.

At Column 13, line 5, "phenylalamine" should be -- phenylalanine --.

At Column 14, line 39, "IN" should be -- In --.

At Column 14, line 61, "using through" should be -- using --.

At Column 15, line 1, "constructed" should be -- constructed, --.

At Column 16, line 18, "Included %" should be -- Included --.

At Column 17, line 42, "huE3apolypeptide" should be -- huE3a polypeptide --.

At Column 19, lines 25-26, "normative" should be -- nonnative --.

At Column 21, line 33, "diagonal" should be -- diagonal" --.

At Column 21, line 36, "penalty." should be -- penalty --.

At Column 30, line 38, "refers a" should be -- refers to a --.

At Column 32, line 57, "example, using an" should be -- example, an --.

At Column 34, line 8, "6 kD" should be -- 6 kDa --.

At Column 34, line 9, "carbohydrat-based" should be -- carbohydrate-based --.

At Column 37, line 47, "about." should be -- about --.

At Column 39, line 40, "set of has" should be -- set of test molecules has --.

At Column 40, line 33, "to polypeptide" should be -- to the polypeptide --.

At Column 45, line 59, "isonixim" should be -- isonixirn --.


At Column 46, line 2, "KCNTE16090" should be -- KCNTE16090 --.

At Column 46, lines 46-47, "triaamcinolone acetonide" should be -- triamcinolone acetonide

MAILING ADDRESS OF SENDER (Please do not use customer number below): Lynn L. Janulis

MARSHALL, GERSTEIN & BORUN LLP 233 S. Wacker Drive, Suite 6300

Sears Tower Chicago, Illinois 60606-6357 2



# UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

Page <u>3</u> of <u>4</u>

At Column 46, line 64, "aurothioglycamide" should be -- aurothioglycanide --.

At Column 47, line 35, "cephalosporinns" should be -- cephalosporins --.

At Column 54, line 63, "527.1994" should be -- 527, 1994 --.

At Column 55, line 24, "sequence. (c)" should be -- sequence, (c)--.

At Column 56, line 27, "5,106.627" should be -- 5,106,627 --.

At Column 59, line 11, "constrict" should be -- construct --.

At Column 61, line 19, "85oC" should be -- 85°C --.

At Column 62, lines 62-63, "clone of was" should be -- clone was --.

At Column 63, line 24, "hour" should be -- hours --.

At Column 63, line 35, "inclcuding" should be -- including --.

At Column 64, lines 58-59, "Edition", Edition," should be -- Edition, --.

At Column 65, line 37, "oil" should be -- on --.

At Column 65, line 52, "0.20%" should be -- 20% --.

At Column 66, line 52, "follows: 5" should be -- follows: --.

At Column 67, line 45, "50 ug/ml" should be -- 50 µg/ml --.

At Column 68, line 7, "MgCl2" should be -- MgCl2 --.

At Column 68, line 56, "epitroclielaris" should be -- epitrochelaris --.

At Column 69, line 31, "MgCl2" should be -- MgCl2 --.

At Column 69, line 34, "1251" should be -- 1251 --.

At Column 70, line 16, "avaiblae" should be -- available --.

Chicago, Illinois 60606-6357

## UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

Page <u>4</u> of <u>4</u>

At Column 71, line 43, "tehrere" should be -- there --.

At Column 71, line 47, "decease" should be -- decrease --.

In the Claims:

At Column 165, line 60, "(a); or (b)" should be -- (a) --.

At Column 165, line 64, "to any" should be -- to the full length of any --.

MAILING ADDRESS OF SENDER (Please do not use customer number below): Lynn L. Janulis MARSHALL, GERSTEIN & BORUN LLP 233 S. Wacker Drive, Suite 6300

**Sears Tower** 

